TrialCancer science2016

Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial.

Ming Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.